US FDA approves Scholar Rock's muscle weakness drug
11/09/2026 22:24
US FDA approves Scholar Rock's muscle weakness drug Sept 11 (Reuters) - The U.S. Food and Drug Administration on Friday approved Scholar Rock's SRRK.O therapy to treat a rare genetic condition that causes muscle weakness.
(Reporting by Sneha S K in Bengaluru; Editing by Tasim Zahid)
Recent news on Novo Nordisk A/S
See all newsFocus: Beauty giants target 'Ozempic face' as boom in obesity drugs opens new market
Factbox: Anthropic's public benefit fund and how it compares with other big philanthropic efforts
Novo's CagriSema helped women lose 25% of weight on average, analysis shows
As weight-loss drug users turn to dietary supplements, doctors, regulators raise flags
Factbox: Major drugmakers turn to China for licensing deals